{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-09-04T05:55:34.540577+00:00","company":{"ticker":"FZMD","cik":319016,"company_name":"Fuse Medical, Inc."},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"earnings_release","fact_key":"40758f55077549174ba4f1892b7f318471406e6c","cik":319016,"ticker":"FZMD","company_name":"Fuse Medical, Inc.","filed_at":"2023-08-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$307,588","period_text":"second quarter ending June 30, 2023","report_date":"2023-08-15","result_type":"reported_results","revenue_text":"$5.0 million"},"claim":"Fuse Medical, Inc. reported second quarter ending June 30, 2023 results: revenue $5.0 million, net income $307,588.","evidence_excerpt":"quarter ended June 30, 2023 with the Securities and Exchange Commission (“SEC”). Second Quarter 2023 Financial Highlights ● Net revenues for the quarter ended June 30, 2023 were $5.0 million, compared to $4.7 million for the quarter ended June 30, 2022 which was an increase of approximately 7%. ● For the quarter ended June 30, 2023, gross profit was $3.5 million, or","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-023797","anchor_url":"https://secwatch.observer/filing/0001437749-23-023797#claim-40758f55077549174ba4f1892b7f318471406e6c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/319016/000143774923023797/0001437749-23-023797-index.htm"},{"fact_type":"shareholder_vote","fact_key":"945061acc52dd1a23814fab26d80149e5d5c8efc","cik":319016,"ticker":"FZMD","company_name":"Fuse Medical, Inc.","filed_at":"2023-06-26T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-23","outcome":"passed","proposal_text":"Ratification of the Selection of M&K CPAS, PLLC","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"191","votes_against":"47,224","votes_for":"64,474,346","votes_withheld":null}]},"claim":"Fuse Medical, Inc. shareholders approved Ratification of the Selection of M&K CPAS, PLLC at the 2023-06-23 meeting.","evidence_excerpt":"The selection of M&K to act as an independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 was ratified by a vote of (i) 64,474,346 in favor, (ii) 47,224 against, and (iii) 191 abstaining.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-018375","anchor_url":"https://secwatch.observer/filing/0001437749-23-018375#claim-945061acc52dd1a23814fab26d80149e5d5c8efc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/319016/000143774923018375/0001437749-23-018375-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a6a813973d5e2cff55d31331b4f05043ffba8c9f","cik":319016,"ticker":"FZMD","company_name":"Fuse Medical, Inc.","filed_at":"2023-06-26T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-23","outcome":"passed","proposal_text":"Election of Board of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"1,372,464","subject":"Renato V. Bosita, Jr., MD","votes_abstain":null,"votes_against":"61,351","votes_for":"63,087,944","votes_withheld":"2"},{"broker_non_votes":"1,372,464","subject":"Mark W. Brooks","votes_abstain":null,"votes_against":"16,447","votes_for":"63,132,848","votes_withheld":"2"},{"broker_non_votes":"1,372,464","subject":"Lawrence S. Yellin","votes_abstain":null,"votes_against":"57,447","votes_for":"63,091,848","votes_withheld":"2"},{"broker_non_votes":"1,372,464","subject":"Christopher C. Reeg","votes_abstain":null,"votes_against":"16,441","votes_for":"63,132,854","votes_withheld":"2"}]},"claim":"Fuse Medical, Inc. shareholders approved Election of Board of Directors at the 2023-06-23 meeting.","evidence_excerpt":"The following persons were elected as directors of the Company for a one-year term expiring at the 2024 Annual Meeting of Stockholders with the following vote: Name Votes For Votes Against Votes Withheld Broker Non-Votes Renato V. Bosita, Jr., MD 63,087,944 61,351 2 1,372,464 Mark W. Brooks 63,132,848 16,447 2 1,372,464 Lawrence S. Yellin 63,091,848 57,447 2 1,372,464 Christopher C. Reeg 63,132,854 16,441 2 1,372,464","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-018375","anchor_url":"https://secwatch.observer/filing/0001437749-23-018375#claim-a6a813973d5e2cff55d31331b4f05043ffba8c9f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/319016/000143774923018375/0001437749-23-018375-index.htm"},{"fact_type":"earnings_release","fact_key":"d1f5862fd21916a84bbde4ea87141bf9deef71a1","cik":319016,"ticker":"FZMD","company_name":"Fuse Medical, Inc.","filed_at":"2023-04-18T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$3.1 million","period_text":"the year ended December 31, 2022","report_date":"2023-04-18","result_type":"reported_results","revenue_text":"$18.6 million"},"claim":"Fuse Medical, Inc. reported the year ended December 31, 2022 results: revenue $18.6 million, net income $3.1 million.","evidence_excerpt":"Net revenues for the year ended December 31, 2022 were $18.6 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-23-005823","anchor_url":"https://secwatch.observer/filing/0001564590-23-005823#claim-d1f5862fd21916a84bbde4ea87141bf9deef71a1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/319016/000156459023005823/0001564590-23-005823-index.htm"},{"fact_type":"auditor_change","fact_key":"c1e3963765df44926c3f7f8dc7e15b3a9823358c","cik":319016,"ticker":"FZMD","company_name":"Fuse Medical, Inc.","filed_at":"2022-11-22T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"M&K PLLC","disagreement_text":null,"effective_date":"2022-11-17","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Fuse Medical, Inc. engaged M&K PLLC as its auditor.","evidence_excerpt":"On November 17, 2022, the Board approved the appointment of M&K PLLC (“M&K”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-22-038196","anchor_url":"https://secwatch.observer/filing/0001564590-22-038196#claim-c1e3963765df44926c3f7f8dc7e15b3a9823358c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/319016/000156459022038196/0001564590-22-038196-index.htm"},{"fact_type":"earnings_release","fact_key":"a07fc1021da86f16cc68b49da0db25f3be9fd06a","cik":319016,"ticker":"FZMD","company_name":"Fuse Medical, Inc.","filed_at":"2022-11-18T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss was $9,376","period_text":"third quarter ended September 30, 2022","report_date":"2022-11-15","result_type":"reported_results","revenue_text":"$4.5 million"},"claim":"Fuse Medical, Inc. reported third quarter ended September 30, 2022 results: revenue $4.5 million, net income net loss was $9,376.","evidence_excerpt":"Net revenues for the quarter ended September 30, 2022 were $4.5 million, compared to $4.2 million for the quarter ended September 30, 2021 which was an increase of approximately 7%.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001564590-22-038045","anchor_url":"https://secwatch.observer/filing/0001564590-22-038045#claim-a07fc1021da86f16cc68b49da0db25f3be9fd06a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/319016/000156459022038045/0001564590-22-038045-index.htm"},{"fact_type":"executive_change","fact_key":"f6fbf6503b","cik":319016,"ticker":"FZMD","company_name":"Fuse Medical, Inc.","filed_at":"2022-04-08T23:59:59+00:00","payload":{"action":"ceased providing interim CFO services","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2022-04-04","interim":false,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":"Lawrence S. Yellin","successor_named":true},"claim":"John S. Gross departed as Interim Chief Financial Officer at Fuse Medical, Inc..","evidence_excerpt":"Effective April 4, 2022, John S. Gross ceased providing the Company with interim CFO services pursuant to the Company’s engagement agreement with CFO Consulting Partners, LLC.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-013944","anchor_url":"https://secwatch.observer/filing/0001564590-22-013944#claim-f6fbf6503b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/319016/000156459022013944/0001564590-22-013944-index.htm"},{"fact_type":"executive_change","fact_key":"40b539d7a9","cik":319016,"ticker":"FZMD","company_name":"Fuse Medical, Inc.","filed_at":"2022-04-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-04-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lawrence S. Yellin was appointed as Director at Fuse Medical, Inc..","evidence_excerpt":"Effective April 4, 2022, the Board of Directors of the Company (the “Board”) has appointed Lawrence S. Yellin as Chief Financial Officer (CFO) and Treasurer of the Company and as a member of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-013944","anchor_url":"https://secwatch.observer/filing/0001564590-22-013944#claim-40b539d7a9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/319016/000156459022013944/0001564590-22-013944-index.htm"},{"fact_type":"executive_change","fact_key":"25078a8577","cik":319016,"ticker":"FZMD","company_name":"Fuse Medical, Inc.","filed_at":"2022-04-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-04-04","interim":false,"role":"Chief Financial Officer and Treasurer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Lawrence S. Yellin was appointed as Chief Financial Officer and Treasurer at Fuse Medical, Inc..","evidence_excerpt":"Effective April 4, 2022, the Board of Directors of the Company (the “Board”) has appointed Lawrence S. Yellin as Chief Financial Officer (CFO) and Treasurer of the Company and as a member of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-013944","anchor_url":"https://secwatch.observer/filing/0001564590-22-013944#claim-25078a8577","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/319016/000156459022013944/0001564590-22-013944-index.htm"},{"fact_type":"executive_change","fact_key":"3543846e83","cik":319016,"ticker":"FZMD","company_name":"Fuse Medical, Inc.","filed_at":"2021-12-03T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2021-11-29","interim":false,"role":"Chief Financial Officer and Director","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"William E. McLaughlin, III resigned as Chief Financial Officer and Director at Fuse Medical, Inc..","evidence_excerpt":"On November 29, 2021, William E. McLaughlin, III resigned as Chief Financial Officer and as a Director of the Board of Fuse Medical, Inc. (the “Company”) as well as from all other positions Mr. McLaughlin held with the Company and its subsidiaries.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-347747","anchor_url":"https://secwatch.observer/filing/0001193125-21-347747#claim-3543846e83","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/319016/000119312521347747/0001193125-21-347747-index.htm"}]}